Article Text

Download PDFPDF

THU0161 Syndecans are correlated with high titres of antibodies against citrullinated proteins antigens (ACPAS) in sera from active rheumatoid arthritis
  1. NA Rodriguez-Jimenez1,
  2. EG Cardona-Muñoz2,
  3. JI Gamez-Nava1,
  4. EE Perez-Guerrero3,
  5. M Ponce-Guarneros4,
  6. EY Vera-Navarrete3,
  7. A Nava-Zavala1,
  8. TA Garcia-Cobian2,
  9. M Salazar-Paramo1,
  10. L Gonzalez-Lopez5
  1. 1UMAE, Hospital de Especialidades Centro Medico de Occidente, Instituto Mexicano del Seguro Social
  2. 2Universidad de Guadalajara, Guadalajara, Mexico
  3. 3Doctorado en Farmacologia, Universidad de Guadalajara, Guadalajara
  4. 4Unidad de Medicina Familiar No. 97, IMSS, Magdalena, Jalisco
  5. 5Hospital General Regional No. 110, IMSS, Guadalajara, Mexico


Background Syndecans includes a group of proteins from the cell-surface heparan-sulfate proteoglycan family, with a relevant role in chronic inflammation of synovial tissue in patients with rheumatoid arthritis (RA) participating in the cell-matrix and cell-cell interactions. Syndecans are differentially expressed in the synovial tissue: syndecan-1 (SDC-1) is expressed mainly in mononuclear cells, syndecan-3 (SDC-3) is mainly expressed by synovial endothelial cells and syndecan-4 (SDC-4) is expressed by B lymphocytes regulating B cell development and survival. Currently, there is strong evidence that antibodies directed to citrullinated protein antigens (ACPAs) are associated with a more severe disease in RA. Nevertheless, to date, there is a lack of information about the relation between serum syndecan levels and serum concentrations of rheumatoid factor (RF) and ACPAs.

Objectives To evaluate the association between serum SDC-1, SDC-3 and SDC-4 levels with serum concentrations of RF and ACPAs.

Methods Eighty-one, patients with RA were included. We assessed clinical characteristics including disease activity by DAS-28, functioning by HAQ-Di. Serum concentrations of RF were measured by nephelometry, two ACPAs were measured: anti-CCP2 and anti-mutated citrullinated vimentin (anti-MCV) antibodies using ELISA. Serum levels of SDC-1, SDC-3 (ng/mL) and SDC-4 (pg/mL) were measured by ELISA. We compared the serum levels of these syndecans in the ACPA+ group (group 1) versus ACPA- group (group 2) with Student t-test. A correlation analysis (Pearson tests) was performed to identify the strength of association between concentrations of syndecans with concentrations of ACPAs and other variables.

Results Patients with RA had a mean age of 50±11 yrs, 75% were RF+ and 64% were ACPA+. In patients with ACPAs+ were observed higher serum concentrations of SDC-3 (p=0.003) and SDC-4 (p<0.001). SDC-1 correlated significantly with anti-MCV (r=0.53, p<0.001). Serum concentrations of SDC-3 correlated significantly with anti-CCP titres (r=0.53, p=0.003) and anti-MCV (r=0.46, p=0.02); whereas SDC-4 levels correlated significantly with anti-CCP titres (r=0.61, p<0.001) and RF (r=0.53, p=0.003). Additionally, serum SDC-1 levels correlated with decrement in response to treatment with synthetic DMARDs (r=-0.25, p=0.026). SDC-1 did not correlate with serum SDC-3 (p=0.8) and SDC-4 (p=0.8); whereas serum SDC-3 and SDC-4 had a strong correlation (r=0.8, p<0.001).

Conclusions Serum SDC-3 and SDC-4 are increased in ACPA-positive RA patients. These data suggest that syndecans might be useful as serum biomarkers for discriminate a group of patients with RA and more severe disease.


  1. Patterson AM, et al. Ann Rheum Dis. 2008 May;67(5):592–601.

  2. Endo T, et al. Arthritis Rheumatol. 2015 Sep;67(9):2512–22.


Acknowledgements This project was supported by a grant from the Fondo de Investigacion en Salud del Instituto Mexicano del Seguro Social: FIS/IMSS/PROT/G15/1448.

Disclosure of Interest N. Rodriguez-Jimenez: None declared, E. Cardona-Muñoz: None declared, J. Gamez-Nava: None declared, E. Perez-Guerrero: None declared, M. Ponce-Guarneros: None declared, E. Vera-Navarrete: None declared, A. Nava-Zavala: None declared, T. Garcia-Cobian: None declared, M. Salazar-Paramo: None declared, L. Gonzalez-Lopez Grant/research support from: Dr. L Gonzalez-Lopez is a recipient of a Fundacion IMSS Scholarship, Mexico.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.